MAGIC: Study Design and Rationale for the Phase 2 Clinical Trial of Faricimab for Non-Proliferative Diabetic Retinopathy
MAGIC is a randomized clinical trial that assesses RNP progression among eyes with NPDR, including its natural history and the impact of faricimab. Its innovative study design also explores the utility of novel assessments of retinal physiology and function.
Authors
- William A. Pearce
- Effie Z. Rahman
- Luis Alfonso Lesmes
- Ahmad Sahraravand
- Avery Zhou
- Francesco Arba (ORCID: https://orcid.org/0000-0003-3941-7383)
- Kenneth C. Fan (ORCID: https://orcid.org/0000-0002-4453-9337)
- Dante J. Pieramici
- Abdhish R. Bhavsar
- Varun Chaudhary
- Lasse Jørgensen Cehofski
- Hasenin Al-khersan
- Srinivas R. Sadda
- Michael Ip
- Matthew A. Cunningham
- David M. Brown
- Daniel Virgil Alfaro
- Justis P. Ehlers
- Charles C. Wykoff
- Jeremiah Brown
- Robert W. Wong
- Margaret Chang
- Liisa M. Baumann
- Gail Megan Teagle
- Sarah E. Holy
- Michael J. Borne
Publication Details
- Journal
- Ophthalmologica
- Published
- 2026-01-26
- DOI
- https://doi.org/10.1159/000550491
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00